Comparative Pharmacology
Head-to-head clinical analysis: ALPHACAINE versus PRILOCAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHACAINE versus PRILOCAINE HYDROCHLORIDE.
ALPHACAINE vs PRILOCAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Prilocaine hydrochloride is an amino amide local anesthetic that reversibly blocks sodium channels in nerve cell membranes, inhibiting nerve impulse propagation.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
Adults: 4 mg/kg (max 200 mg) via infiltration or nerve block; may repeat after 2 hours with 50% of initial dose.
None Documented
None Documented
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Terminal half-life: 1.5-2 hours (adults, normal hepatic function). Prolonged in neonates (up to 8-12 hours) due to immature hepatic metabolism and reduced clearance; may cause methemoglobinemia. Hepatic impairment increases half-life.
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Renal: ~95% as metabolites (primarily o-toluidine and 4-hydroxy-2-methylaniline) and <5% unchanged. Biliary/fecal: minimal (<2%).
Category C
Category C
Local Anesthetic
Local Anesthetic